Kronos Bio Inc
NASDAQ:KRON

Watchlist Manager
Kronos Bio Inc Logo
Kronos Bio Inc
NASDAQ:KRON
Watchlist
Price: 0.94 USD -1.87%
Market Cap: 56.7m USD
Have any thoughts about
Kronos Bio Inc?
Write Note

Kronos Bio Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kronos Bio Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Kronos Bio Inc
NASDAQ:KRON
Net Income (Common)
-$112.7m
CAGR 3-Years
-8%
CAGR 5-Years
-76%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$126m
CAGR 3-Years
-74%
CAGR 5-Years
-46%
CAGR 10-Years
-35%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Kronos Bio Inc
Glance View

Market Cap
56.7m USD
Industry
Biotechnology

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. The company is headquartered in San Mateo, California and currently employs 96 full-time employees. The company went IPO on 2020-10-09. The firm is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine’s small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Its KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).

KRON Intrinsic Value
1.03 USD
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Kronos Bio Inc's Net Income (Common)?
Net Income (Common)
-112.7m USD

Based on the financial report for Dec 31, 2023, Kronos Bio Inc's Net Income (Common) amounts to -112.7m USD.

What is Kronos Bio Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-76%

Over the last year, the Net Income (Common) growth was 15%. The average annual Net Income (Common) growth rates for Kronos Bio Inc have been -8% over the past three years , -76% over the past five years .

Back to Top